BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides

Journal of Clinical Pharmacology

Volumn 57, Issue 11, 2017, Pages 1460-1471

  Sakamoto, Kei ^a   Matsuki, Shunji ^a   Matsuguma, Kyoko ^a   Yoshihara, Tatsuya ^a   Uchida, Naoki ^b   Azuma, Fumihiko ^c   Russell, Muir ^c   Hughes, Glen ^c   Haeberlein, Samantha Budd ^c   Alexander, Robert C ^c   Eketjäll, Susanna ^d   Kugler, Alan R ^c  

^a Fukuoka Mirai Hospital Clinical Research Center   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c ASTRAZENECA   (United Kingdom)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

Alzheimer disease; amyloid peptides; BACE1 protein human; cerebrospinal fluid proteins; clinical trials; Japanese; lanabecestat, AZD3293

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; AZ 13569724; BETA SECRETASE 1; DRUG METABOLITE; LANABECESTAT; PLACEBO; UNCLASSIFIED DRUG; 4-METHOXY-5'-METHYL-6'-(5-(PROP-1-YN-1-YL)PYRIDIN-3-YL)-3'H-DISPIRO(CYCLOHEXANE-1,2'-INDEN-1',2'-IMIDAZOL)-4'-AMINE; ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; PEPTIDE FRAGMENT; SECRETASE; SPIRO COMPOUND;

ADULT; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EXCRETION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; JAPANESE (PEOPLE); MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; ORTHOSTATIC HYPOTENSION; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; POSITIONAL DIZZINESS; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; RANDOMIZED CONTROLLED TRIAL; RENAL CLEARANCE; REPEATED DRUG DOSE; RHINOPHARYNGITIS; SINGLE DRUG DOSE; AGED; ANTAGONISTS AND INHIBITORS; ASIAN CONTINENTAL ANCESTRY GROUP; BRAIN; CEREBROSPINAL FLUID; CLINICAL TRIAL; HALF LIFE TIME; METABOLISM; MIDDLE AGED; PLASMA; YOUNG ADULT;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ASIAN CONTINENTAL ANCESTRY GROUP; ASPARTIC ACID ENDOPEPTIDASES; BRAIN; CEREBROSPINAL FLUID; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HEALTHY VOLUNTEERS; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PLASMA; SPIRO COMPOUNDS; YOUNG ADULT;

EID: 85021211381     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.950     Document Type: Article

References (34)

1. Selkoe DJ The molecular pathology of Alzheimer's disease. Neuron. 1991;6(4):487–498.
2. Vassar R BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimer's Res Ther. 2014;6(9):89.
3. WHO. Dementia. Fact sheet number 362. Geneva: World Health Organization, 2015. http://www.who.int/mediacentre/factsheets/fs362/en/. Accessed September 6, 2016.
4. Alzheimer's and Dementia in Japan. http://www.alz.org/jp/dementia-alzheimers-japan.asp. Accessed September 6, 2016.
5. Casey DA, Antimisiaris D, O'Brien J. Drugs for Alzheimer's disease: are they effective? P&T. 2010;35(4):208–211.
6. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (New York, NY). 2002;297(5580):353–356.
7. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10(9):698–712.
8. Menting KW, Claassen JA. Beta-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease. Front Aging Neurosci. 2014;6:165.
9. Yan R, Vassar R. Targeting the beta secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol. 2014;13(3):319–329.
10. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci. 2001;21(2):372–381.
11. Roberds SL, Anderson J, Basi G, et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet. 2001;10(12):1317–1324.
12. Laird FM, Cai H, Savonenko AV, et al. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci. 2005;25(50):11693–11709.
13. McConlogue L, Buttini M, Anderson JP, et al. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice. J Biol Chem. 2007;282(36):26326–26334.
14. Citron M, Oltersdorf T, Haass C, et al. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature. 1992;360(6405):672–674.
15. Cai XD, Golde TE, Younkin SG. Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science (New York, NY). 1993;259(5094):514–516.
16. Suzuki N, Cheung TT, Cai XD, et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science (New York, NY). 1994;264(5163):1336–1340.
17. Mullan M, Crawford F, Axelman K, et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet. 1992;1(5):345–347.
18. Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012;488(7409):96–99.
19. Butini S, Brogi S, Novellino E, et al. The structural evolution of beta-secretase inhibitors: a focus on the development of small-molecule inhibitors. Curr Top Med Chem. 2013;13(15):1787–1807.
20. Oehlrich D, Prokopcova H, Gijsen HJ. The evolution of amidine-based brain penetrant BACE1 inhibitors. Bioorg Med Chem Lett. 2014;24(9):2033–2045.
21. Cebers G, Alexander RC, Haeberlein SB, et al. AZD3293: pharmacokinetic and pharmacodynamic effects in healthy subjects and patients with Alzheimer's disease. J Alzheimer Dis. 2017;55(3):1039–1053.
22. Eketjall S, Janson J, Kaspersson K, et al. AZD3293: a novel, orally active BACE1 inhibitor with high potency and permeability and markedly slow off-rate kinetics. J Alzheimer Dis. 2016;50(4):1109–1123.
23. 14C]-AZD3293. American Association of Pharmaceutical Scientists Annual Meeting (Poster #T3307); 2015; Orlando, FL.
24. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22–33;quiz 34–57.
25. Columbia-Suicide Severity Rating Scale (Japanese Version). 2009. http://www.cssrs.columbia.edu. Accessed September 6, 2016.
26. Vassar R, Kuhn PH, Haass C, et al. Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J Neurochem. 2014;130(1):4–28.
27. Yan R. Stepping closer to treating Alzheimer's disease patients with BACE1 inhibitor drugs. Transl Neurodegener. 2016;5:13.
28. BACE inhibitor BI 1181181 voluntarily put on temporary clinical hold for safety evaluation. 2016. http://ir.vitaepharma.com/phoenix.zhtml?c=219654&p=irol-newsArticle&ID=2020814. Accessed September 6, 2016.
29. Poolsup N, Li Wan Po A, Knight TL. Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther. 2000;25(3):197–220.
30. Kim K, Johnson JA, Derendorf H. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol. 2004;44(10):1083–1105.
31. Min KFM, Dockendorf, M, Palcza J, Soni P, Ma I. A study to evaluate the pharmacokinetics and pharmacodynamics of single and multiple oral doses of the novel BACE inhibitor MK-8931 in Japanese subjects. Alzheimers Dement. 2012;8(4, suppl):P186.
32. Forman M, Kleijn HJ, Dockendorf M, Palcza J, Tseng J, Canales C. The novel BACE inhibitor MK-8931 dramatically lowers CSF beta-amyloid in patients with mild-to-moderate Alzheimer's disease. Alzheimers Dement. 2013;9(4, suppl):P139.
33. May PC, Willis BA, Lowe SL, et al. The potent BACE1 inhibitor LY2886721 elicits robust central Abeta pharmacodynamic responses in mice, dogs, and humans. J Neurosci. 2015;35(3):1199–1210.
34. Henderson SJ, Andersson C, Narwal R, et al. Sustained peripheral depletion of amyloid-beta with a novel form of neprilysin does not affect central levels of amyloid-beta. Brain. 2014;137(Pt 2):553–564.